BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 20127552)

  • 21. Interscience Conference on Antimicrobial Agents and Chemotherapy--49th annual meeting. Part 2. 12-15 September 2009, San Francisco, CA, USA.
    Turner B; Murch L
    IDrugs; 2009 Nov; 12(11):670-2. PubMed ID: 19844847
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Asthma and COPD--SMi's Fifth Annual Conference. 20-21 April 2009, London, UK.
    Macauley D
    IDrugs; 2009 Jun; 12(6):342-5. PubMed ID: 19517311
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interscience Conference on Antimicrobial Agents and Chemotherapy--49th annual meeting. Part 1. 11-15 September 2009, San Francisco, CA, USA.
    Turner B; Murch L
    IDrugs; 2009 Nov; 12(11):667-9. PubMed ID: 19844846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Terrapinn's world influenza congress Europe 2009. Part 2.
    Veryard C
    IDrugs; 2010 Feb; 13(2):78-9. PubMed ID: 20127556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Asthma & COPD--IQPC's Second Conference.
    Catley MC
    IDrugs; 2010 Sep; 13(9):601-4. PubMed ID: 20799138
    [TBL] [Abstract][Full Text] [Related]  

  • 26. World Vaccine Congress Lyon - Terrapinn's 11th Annual Congress.
    Sovran L
    IDrugs; 2009 Dec; 12(12):738-41. PubMed ID: 19943212
    [TBL] [Abstract][Full Text] [Related]  

  • 27. American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 1.
    Croasdell G
    IDrugs; 2010 Sep; 13(9):595-7. PubMed ID: 20799136
    [TBL] [Abstract][Full Text] [Related]  

  • 28. American Society of Hematology--51st annual meeting & exposition. Part 1.
    Shumoogam J; Beecher N
    IDrugs; 2010 Feb; 13(2):57-9. PubMed ID: 20127549
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RNAi for Developing Targeted Therapeutics--CHI's Third Annual Meeting.
    Plane G
    IDrugs; 2010 Jan; 13(1):20-2. PubMed ID: 20024842
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stem Cells - SMi's second annual conference: achieving success in science and commercialisation.
    Lucifero D
    IDrugs; 2010 Apr; 13(4):232-4. PubMed ID: 20373250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. American Diabetes Association--70th scientific sessions--research on novel therapeutics: part 2.
    Croasdell G
    IDrugs; 2010 Sep; 13(9):598-600. PubMed ID: 20799137
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of natural products in drug discovery and development in the new millennium.
    Harvey A
    IDrugs; 2010 Feb; 13(2):70-2. PubMed ID: 20127553
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Key Opinion Leaders - SMi's Second Conference Knowledge Leaders.
    Mason VL
    IDrugs; 2009 Dec; 12(12):770-3. PubMed ID: 19943219
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ion Channels as Therapeutic Targets--CHI's Fourth Annual Conference.
    Thorneloe KS
    IDrugs; 2010 Jan; 13(1):16-9. PubMed ID: 20024841
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Drug Development for Neurodegenerative Diseases--Second Annual marcus evans Conference. Advances in drug development for NDD and expediting discovery through novel compounds and sound clinical trials.
    Morimoto B
    IDrugs; 2010 Jul; 13(7):440-3. PubMed ID: 20582866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A role for fMRI in optimizing CNS drug development.
    Borsook D; Becerra L; Hargreaves R
    Nat Rev Drug Discov; 2006 May; 5(5):411-24. PubMed ID: 16604100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. American Academy of Allergy, Asthma and Immunology (AAAAI)-2010 annual meeting. 26 February-2 March 2010, New Orleans, LA, USA.
    Bielory L
    IDrugs; 2010 May; 13(5):304-7. PubMed ID: 20432184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New drugs in neurology].
    Mattle HP
    Praxis (Bern 1994); 1999 Apr; 88(18):827-34. PubMed ID: 10409881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central nervous system drug development, basic, and clinical research: thinking outside the box.
    Klein DF; Glick ID; Shader RI
    J Clin Psychopharmacol; 2011 Oct; 31(5):553-4. PubMed ID: 21869701
    [No Abstract]   [Full Text] [Related]  

  • 40. Drug Development for Neurodegenerative Diseases--a marcus evans conference. Expediting drugs to the market for neurodegenerative disease indications through novel translational efforts, regulatory clarity, and sound trial design. 7-8 April 2009, Boston, MA, USA.
    Morimoto B
    IDrugs; 2009 Jun; 12(6):349-52. PubMed ID: 19517313
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.